bluebird bio Inc (NASDAQ:BLUE) shares are surging 25% after releasing interim results from the firm’s Phase 1 trial of its anti-BCMA CAR T …
In a research report released Friday, BTIG analyst Dane Leone reiterated a Buy rating on shares of Celgene Corporation (NASDAQ:CELG) with a price target …
While Juno Therapeutics Inc (NASDAQ:JUNO) rides a positive tide following an abstract release from The American Society of Hematology (ASH), shares are rising …
Everyone’s favorite troubled biotech giant Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is making the news cycles rumble once again with official talks that the firm’s …
In a research report published Monday, BTIG analyst Mark Palmer reiterated a Buy rating on shares of LendingClub Corp (NYSE:LC) with a price target …
Amid a merger and acquisition fever, with AT&T Inc. (NYSE:T) and Genworth Financial Inc (NYSE:GNW) announcing pivotal deals yesterday, analysts are chiming in on …
Analysts from BTIG and Webush are sharing insights on two falling stocks: Imperva Inc (NYSE:IMPV), whose shares are crashing close to 15% today, and …
BTIG analysts are weighing in with contrasting viewpoints on Facebook Inc (NASDAQ:FB) and Paypal Holdings Inc (NASDAQ:PYPL). Whereas one analyst stands by his …
BTIG analyst Tim Chiang dives in on Synergy Pharmaceuticals Inc (NASDAQ:SGYP) after recent meetings with management have bolstered his positivity on the firm’s shares. As …
Ocular Therapeutix Inc (NASDAQ:OCUL) shares popped nearly 14% yesterday, after the biopharmaceutical company announced a $10 million drug development deal with Regeneron Pharmaceuticals Inc (NASDAQ:REGN) …
